Rational sequence of monoclonal antibodies in the treatment of non-resectable head and neck squamous cell carcinoma [Рациональная последовательность моноклональных антител в лечении нерезектабельного плоскоклеточного рака головы и шеи]

This article discusses current approaches to first-line chemotherapy for non-resectable head and neck squamous cell carcinoma and describes factors affecting the choice of treatment regimen according to the results of randomized clinical trials. we provide a rationale for creating a long-term strategy of chemotherapy in different clinical situations. we also report two cases of concomitant administration of cetuximab and platinum-based therapy as an example of high efficacy of monoclonal antibodies. © 2022 Farmatsiya i Farmakologiya. All rights reserved.

Авторы
Bolotina L.V. 1 , Ustinova T.V. 1 , Dеshkina T.I.1 , Golubev P.V.1 , Lyubavina N.N.1 , Fedenko A.A.1 , Kaprin A.D. 1, 2
Номер выпуска
1
Язык
Русский
Страницы
35-52
Статус
Опубликовано
Том
12
Год
2022
Организации
  • 1 P.A. Herzen Moscow Oncology Research Institute, A Branch of the National Medical Radiology Research Center, Ministry of Health of Russia, 3 2nd Botkinsky proezd, Moscow, 125284, Russian Federation
  • 2 Рeoples' Friendship University of Russia, 6 Miklukho-Maklaya St., Moscow, 117198, Russian Federation
Ключевые слова
cetuximab; chemotherapy; head and neck tumors; immunotherapy; monoclonal antibodies
Дата создания
06.07.2022
Дата изменения
06.07.2022
Постоянная ссылка
https://repository.rudn.ru/ru/records/article/record/83982/
Поделиться

Другие записи